糖尿病是一种多因素参与缓慢发展的代谢疾病,随着病情发展可影响多个组织器官功能。已知胰岛素抵抗、氧化应激、慢性炎症等因素在糖尿病及其并发症如动脉粥样硬化、肾功能不全等的发生、发展中起着不可忽视的作用。吡格列酮是噻唑烷二酮类(thiazolidinedione,TZDs)胰岛素增敏剂,作用于过氧化物酶体增殖物激活受体。近年研究发现TZDs不仅有改善胰岛素抵抗、降血糖的作用,还具有降低血压、降低血脂、抗氧化应激、抗炎以及抗纤维化等作用。 Diabetes is a multi-factor involved in the slow development of metabolic diseases, with the progression of the disease can affect multiple tissue and organ function. It is known that factors such as insulin resistance, oxidative stress and chronic inflammation play an irreversible role in the occurrence and development of diabetes and its complications such as atherosclerosis and renal insufficiency. Pioglitazone is a thiazolidinedione (TZDs) insulin sensitizer that acts on peroxisome proliferator-activated receptors. In recent years, studies have found that TZDs not only improve insulin resistance, hypoglycemic effect, but also lower blood pressure, lower blood lipids, anti-oxidative stress, anti-inflammatory and anti-fibrosis and so on.